Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study
Simon D., Yousefi S., Cazzaniga S., Bürgler C., Radonjic S., Houriet C., Heidemeyer K., Klötgen H. -., Kozlowski E., Borradori L., Simon Kh.
Allergy
Vol.75, Issue3, P. 669-672
Опубликовано: 2020
Тип ресурса: Письмо
Аннотация:
[краткое описание не найдено]
Ключевые слова:
bullous pemphigoid; eosinophil; interleukin-5; mepolizumab
gamma interferon; interleukin 13; mepolizumab; placebo; prednisolone; add on therapy; bullous pemphigoid; controlled study; corticosteroid therapy; dermatitis; dermoepidermal junction; double blind procedure; drug efficacy; drug safety; drug withdrawal; eosinophil; human; intention to treat analysis; Letter; mast cell; parallel design; pilot study; priority journal; randomized controlled trial; recurrence free survival; relapse; T lymphocyte; treatment failure
Язык текста: Английский
ISSN: 1398-9995
Simon D.
Yousefi S.
Cazzaniga S.
Bürgler C.
Radonjic S.
Houriet C.
Heidemeyer K.
Klötgen H. -. H.-W.
Kozlowski E.
Borradori L.
Simon Kh. Khans-Uve 1958-
Симон Д.
Ёусефи С.
Cаззанига С.
Бüрглер C.
Радонйиc С.
Хоуриет C.
Хеидемеьер К.
Клöтген Х. -. Х.-W.
Козлоwски Е.
Боррадори Л.
Симон Х. Ханс-Уве 1958-
Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study
Текст визуальный непосредственный
Allergy
Munksgaard International Publishers
Vol.75, Issue3 P. 669-672
2020
Письмо
bullous pemphigoid eosinophil interleukin-5 mepolizumab
gamma interferon interleukin 13 mepolizumab placebo prednisolone add on therapy bullous pemphigoid controlled study corticosteroid therapy dermatitis dermoepidermal junction double blind procedure drug efficacy drug safety drug withdrawal eosinophil human intention to treat analysis Letter mast cell parallel design pilot study priority journal randomized controlled trial recurrence free survival relapse T lymphocyte treatment failure
[краткое описание не найдено]